A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Inclusion Criteria: * Female subjects aged 18 to 40 years old at Screening visit * Diagnosis of PCOS (either historical or during Screening) according to NIH (1990) criteria * DHEAS level \> age-matched upper limit of normal (ULN) at Screening visit * Agree to follow industry standard contraception guidelines within protocol Exclusion Criteria: * Evidence of: 1. History of congenital adrenal hyperplasia (CAH), Cushing's syndrome, pituitary or adrenal disease 2. Clinically significant hyperprolactinemia 3. Thyroid stimulating hormone (TSH) \<0.1 mU/mL or \>4.5mU/mL at Screening 4. Cortisol levels concerning for adrenal insufficiency 5. Other findings suggestive of secondary cause for anovulation and/or hyperandrogenemia * Total testosterone levels \>140 ng/dL, DHEAS \>650 mcg/dL, virilization or other signs or symptoms concerning for ovarian hyperthecosis or androgen-secreting tumors * Medical conditions that require glucocorticoid treatment within 30 days of screening and throughout the duration of the study * Clinically significant unstable medical conditions, illness, or chronic diseases * Prior hysterectomy or bilateral oophorectomy * Females who are pregnant or nursing